Welcome to the November issue! Half a million lives have been lost to the US opioid crisis over the past 30 years: our cover feature examines pharma’s role. In Upfront, you can find out how researchers are harnessing bacterial viruses to improve drug delivery to the brain; while Nik Kotecha gives his thoughts on mitigating Brexit supply chain risks in In My View. In Business, Letrishka Anthony asks whether ADCs could finally move to the forefront in the targeted therapy space; and we Sit Down With Tony Hitchcock, Technical Director of Cobra Biologics, Keele, UK.
December 4, 2019
More complex proteins are coming down the pipe, but bispecifics and other novel format antibodies or glycoproteins – with domains combined from various molecules and unnatural engineered elements – can’t always be easily shoehorned into existing platforms. Instead, next-generation protein expression will require a toolbox of next-generation solutions.
0 min read
December 3, 2019
Successes in the clinic have placed many cell and gene therapies on an accelerated route to market. But unless developers consider, at an early stage, how they might produce their product at scale, they may run into problems with commercial manufacturing. Here, we present an article based on an interview with Carol Knevelman (Vice President, Head of Process R&D at Oxford Biomedica), who shared a case study on large scale lentiviral vector production at Cytiva’s “Bioprocess Days” event in May, 2019. Carol offers her advice for developing a futureproof commercial process.
0 min read
December 2, 2019
Single-use systems must be designed with the end-user in mind – because user-friendly technologies help ensure the best product performance, reduce the risk of user error and, ultimately, improve product quality
0 min read
November 27, 2019
Continuous processing, exporting generics and alleviating drug shortages… what’s new for pharma in business?
1 min read
November 27, 2019
To what extent is the pharmaceutical industry responsible for the USA opioid crisis – and the half a million lives lost over the past three decades?
1 min read
November 26, 2019
A new campaign highlights how far businesses have to go to close the gender pay gap – and pharma is no exception
1 min read
November 25, 2019
After disappointment comes success. After a new approval and multi-million dollar deals, are ADCs finally moving to the forefront in the targeted therapy space?
0 min read
November 21, 2019
Why are people still being prescribed giant tablets?
1 min read
November 19, 2019
The EMA recommends MSD’s Ebola vaccine for approval
1 min read
November 18, 2019
Step into the design space... and your life will be changed forever.
1 min read
November 18, 2019
With many companies embracing the move to next generation bioprocessing, it is important that they do not forget to re-examine their approach to viral safety.
1 min read
November 14, 2019
Sitting Down With… Tony Hitchcock, Technical Director, Cobra Biologics, Keele, UK.
1 min read
November 13, 2019
How can we protect patients against drug–drug interactions and adverse drug reactions?
1 min read
November 12, 2019
Researchers harness bacterial viruses to improve drug delivery to the brain
1 min read
November 12, 2019
The deadline for the EU’s Falsified Medicines Directive has come and gone, but have industry’s concerns dissipated? And what new challenges could a no-deal Brexit bring?
1 min read
November 6, 2019
Brexit is a serious challenge for UK businesses trading with the EU – but there are a number of actions companies can take to mitigate the risk to supply chains.
1 min read
